Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Adlai Nortye Ltd V.ANL.H


Primary Symbol: ANL

Healthcare Biotechnology
Adlai Nortye Ltd is a Cayman Island-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.


NDAQ:ANL - Post by User

Adlai Nortye Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Msimmons22on Jul 13, 2018 9:34am
111 Views
Post# 28311267

TZR (Terrace Energy) - Get in NOW - Multi Bagger opportunity

TZR (Terrace Energy) - Get in NOW - Multi Bagger opportunityNews could be in store shortly, Something is a Brewing!
 
Scorching the Market today early!!!!!!!!
 
the Company is pursuing the sale of its interest in the Maverick County Project which could bring in big money!!!
 
Over 500k Volume on opening, up +50%
 
Legitimate Multi bagger today as asks are Ultra thin and bids are building up large.
 
Everyone is in for a big treat.
 
Unlike some of the other high volume stocks on the Venture today this one actually has leadership moving in the right direction as of late. Sale of Maverick could be HUGE!!!!
 
Could be a great day for all who get involved here! :)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities